Kurzfassung

Aim of TP B18N is the pharmaceutical, preclinical and clinical development of a novel nanoparticular vaccination platform for the treatment of patients with polyoma virus associated merkel cell carcinoma (PyV-MCC). Firstly, we will establish a suitable application format for our patented transcutaneous immunization method to test tolerability and efficacy in a polyoma virus induced tumor model and analyze the modes of action. Beyond this, the formal prerequisites for conduction of a clinical...Aim of TP B18N  is the pharmaceutical, preclinical and clinical development of a novel nanoparticular vaccination platform for the treatment of patients with polyoma virus associated merkel cell carcinoma (PyV-MCC). Firstly, we will establish a suitable application format for our patented transcutaneous immunization method to test tolerability and efficacy in a polyoma virus induced tumor model and analyze the modes of action. Beyond this, the formal prerequisites for conduction of a clinical study in PyV-MCC patients will be installed.» weiterlesen» einklappen